Trials / Conditions / MPS II
MPS II
7 registered clinical trials studyying MPS II — 2 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Suspended | RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome) NCT07236606 | REGENXBIO Inc. | Phase 3 |
| Terminated | MPS II Immunophenotyping NCT04976231 | Duke University | — |
| Recruiting | PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders) NCT04532047 | University of California, San Francisco | Phase 1 |
| Completed | An Extension Study to Assess the Long-term Safety and Efficacy of Hunterase (Idursulfase Beta) NCT07344376 | GC Biopharma Corp | Phase 3 |
| Terminated | Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With M NCT03041324 | Sangamo Therapeutics | Phase 1 / Phase 2 |
| Recruiting | Longitudinal Study of Neurodegenerative Disorders NCT03333200 | University of Pittsburgh | — |
| Completed | Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Ther NCT00607386 | Shire | Phase 4 |